<DOC>
	<DOC>NCT02269605</DOC>
	<brief_summary>Phase I, randomized, double blind, placebo-controlled, dose-finding trial. The trialÂ´s goal is to evaluate two different doses of Bryostatin on HIV-1 latency and reservoir in HIV-1 infected patients receiving antiretroviral treatment.</brief_summary>
	<brief_title>Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Bryostatin 1</mesh_term>
	<criteria>Patients understanding the trial purpose Patients between 18 and 50 years of age Patients with chronic HIV1 infection Patients receiving antiretroviral treatment with at least 3 active drugs for at least 2 years Undetectable viral load measured by ultra sensitive methods CD4+ levels higher than 350 cells/mm3 Patients committed to use contraceptive methods during the trial and up to 3 months after. Previous antiretroviral treatment failure, as any viral load outbreak after having had undetectable HIV1 load. Low grade, transitory outbreaks (&lt;200 RNA copies/ml) resolved without treatment modifications are excluded Patients planned to interrupt antiretroviral treatment during the trial Patients receiving immunosuppressant or immunostimulant drugs, including valproic acid. Pregnant women Bryostatin1 hypersensitivity Being enrolled in another clinical trial or having participated in another clinical trial in the previous 3 months.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>HIV reservoir</keyword>
	<keyword>Bryostatin</keyword>
</DOC>